SCHEMBL12249201

SCHEMBL12249201

Cc1ccc(-c2csc(NC(=O)c3ccncc3)n2)c(C)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 2/20 0.71
MAPT P10636 4/20 0.61
PARP1 P09874 1/20 0.59
SMN1; SMN2 Q16637 4/20 0.58
CCR6 P51684 1/20 0.58
LMNA P02545 3/20 0.57
KDM4E B2RXH2 1/20 0.57
POLB P06746 1/20 0.57
HPGD P15428 1/20 0.57
RECQL P46063 1/20 0.57
TAS1R3 Q7RTX0 1/20 0.57
TAS1R1 Q7RTX1 1/20 0.57
TAS1R2 Q8TE23 1/20 0.57
TSHR P16473 2/20 0.56
MAPK1 P28482 2/20 0.56
STAT3 P40763 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ADORA3 P0DMS8 1/20 0.55
TYR P14679 3/20 0.53
NFKB1 P19838 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2753844 0.89 TYR (0.67) MPLMAPTPARP1SMN1; SMN2CCR6
SCHEMBL12248933 0.88 MAPT (0.58) MPLMAPTPARP1SMN1; SMN2CCR6
SCHEMBL12248877 0.86 SMN1; SMN2 (0.65) MPLMAPTSMN1; SMN2CCR6LMNA
SCHEMBL26884271 0.85 PARP1 (0.69) MPLMAPTPARP1SMN1; SMN2LMNA
SCHEMBL12248431 0.85 MAPT (0.64) MPLMAPTPARP1SMN1; SMN2CCR6
SCHEMBL24107494 0.85 ADORA3 (0.64) MPLMAPTSMN1; SMN2LMNAKDM4E
SCHEMBL30292491 0.85 ADORA3 (0.64) MPLMAPTSMN1; SMN2LMNAKDM4E
SCHEMBL16607206 0.85 MPL (0.68) MPLMAPTSMN1; SMN2CCR6LMNA
SCHEMBL27986863 0.84 MAPT (0.62) MPLMAPTPARP1SMN1; SMN2CCR6
SCHEMBL4875974 0.84 MPL (1.00) MPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409902-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2016-08-09 US disclosed
US-20150250794-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORP (TW) 2015-09-10 US disclosed
US-8999983-B2 Modulators of Hec1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2015-04-07 US disclosed
US-20150057281-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2015-02-26 US disclosed
US-8946268-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS, INC. (TW) 2015-02-03 US disclosed
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-07-25 US disclosed
US-20110230486-A1 Modulators Of HEC1 Activity And Methods Therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR WEE1, WEE2, NEK11 MPL 4439/4885MAPT 2904/4885PARP1 944/4885
US-20150250794-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR WEE1, WEE2, NEK11 MPL 4439/4885MAPT 2904/4885PARP1 944/4885
US-20150057281-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR WEE1, WEE2, NEK11 MPL 4500/4885MAPT 2820/4885PARP1 1073/4885
US-20110230486-A1 Modulators Of HEC1 Activity And Methods Therefor WEE1, WEE2, NEK11 MPL 4500/4885MAPT 2820/4885PARP1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.